Source comparison
Melanotan-1 vs Melanotan-2: Side-Effect Comparison
Melanotan-1 Mild nausea (8%), injection-site reactions, transient darkening of existing moles MC1R-mediated melanogenesis without systemic receptor activation Low. Resolves without dose adjustment in most cases FDA-approved for EPP and vitiligo under medical s
This comparison does not assign a generated winner or score.
- Melanotan-1
- Mild nausea (8%), injection-site reactions, transient darkening of existing moles
- MC1R-mediated melanogenesis without systemic receptor activation
- Low. Resolves without dose adjustment in most cases
- FDA-approved for EPP and vitiligo under medical supervision
- Melanotan-2
- Spontaneous erections (73% at 0.5mg+), nausea (40–60%), facial flushing, dose-dependent hypertension
- MC4R activation (erectile/libido effects), MC3R activation (nausea), peripheral vasodilation
- Moderate to high. Limits practical dosing; cardiovascular monitoring required
- No regulatory approval; available only through research channels
- Onset Timing
- Pigmentation visible after 7–10 days of dosing
- Erectile/nausea effects within 2–6 hours of injection
- Immediate vs delayed
- .
- Pigmentation Potency
- Gradual eumelanin increase over 4–6 weeks
- Rapid pigmentation within 10–14 days at lower cumulative dose
- Slower but more stable
- Professional Assessment
- Melanotan-1's MC1R selectivity makes it the safer option for pigmentation-focused research or therapeutic use. Melanotan-2's side-effect burden and lack of regulatory approval create meaningful risk. Particularly for individuals with cardiovascular conditions or those unfamiliar with peptide reconstitution protocols.
- If the research goal is melanogenesis without confounding systemic effects, Melanotan-1 is the appropriate analog.
- The bottom line: Melanotan-2's multi-receptor activity is not a design flaw. It was intentional. Early researchers sought a peptide with broader physiological effects, including appetite suppression and sexual enhancement. But those same mechanisms create a side-effect profile that limits its practical use outside controlled research settings.